epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove bictegravir/ emtricitabine/ tenofovir alafenamide
    generic
  • remove Epzicom
    abacavir/ lamivudine
  • remove haloperidol
    generic

multicheck MultiCheck Results - 1 Interaction

Smiley face Smiley face

Avoid/Use Alternative

Smiley face Smiley face bictegravir/emtricitabine/tenofovir alafenamide (generic) + Epzicom (abacavir/ lamivudine)

Avoid/Use Alternative


bictegravir + lamivudine

avoid combo: combo may incr. lamivudine levels, risk of adverse effects (renal transport inhibited; duplicate therapy)

Additional Considerations

Smiley face Smiley face abacavir in Epzicom

some formulations of abacavir contain sorbitol

Smiley face Smiley face lamivudine in Epzicom

avoid combo of lamivudine oral solution with oral products containing sorbitol; may give lamivudine tab formulation or monitor virologic response more frequently if combo cannot be avoided; sorbitol may decr. bioavailability of lamivudine, resulting in decr. levels, efficacy

Smiley face Smiley face tenofovir alafenamide in bictegravir/emtricitabine/tenofovir alafenamide

tenofovir alafenamide (prodrug) converted to tenofovir

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information